The in-vitro activity of moxifloxacin against Legionella species and the effects of medium on susceptibility test results

Journal of Antimicrobial Chemotherapy

Volumn 43, Issue SUPPL. B, 1999, Pages 25-29

  Ruckdeschel, G ^a   Dalhoff, A ^a  

^a BAYER AG   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

2 OXOGLUTARIC ACID; CHARCOAL; CIPROFLOXACIN; ERYTHROMYCIN; MOXIFLOXACIN; QUINOLINE DERIVED ANTIINFECTIVE AGENT; RIFAMPICIN;

ANTIBACTERIAL ACTIVITY; ANTIBIOTIC SENSITIVITY; ARTICLE; CULTURE MEDIUM; DILUTION; LEGIONELLA; LEGIONELLA FEELEII; LEGIONELLA LONGBEACHAE; LEGIONELLA PNEUMOPHILA; MINIMUM INHIBITORY CONCENTRATION; YEAST;

ANTI-BACTERIAL AGENTS; ANTI-INFECTIVE AGENTS; ANTIBIOTICS, ANTITUBERCULAR; AZA COMPOUNDS; CIPROFLOXACIN; CULTURE MEDIA; DRUG RESISTANCE, MICROBIAL; ERYTHROMYCIN; FLUOROQUINOLONES; LEGIONELLA; MICROBIAL SENSITIVITY TESTS; QUINOLINES; RIFAMPIN;

EID: 0032899653     PISSN: 03057453     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (23)

1. Winn, W. C. (1995). Legionella. In Manual of Clinical Microbiology, 6th edn (Murray, P. R., Baron, J. E., Pfoller, M. A., Tenover, F. C. & Yolken, R. H., Eds), pp. 533-44. American Society for Microbiology, Washington, DC.
2. Dalhoff, A., Petersen, U. & Endermann, R. (1996). In vitro activity of BAY 12-8039, a new 8-methoxyquinolone. Chemotherapy 42, 410-25.
3. Rolinson, G. N. & Russell, E. J. (1972). New method for antibiotic susceptibility testing. Antimicrobial Agents and Chemotherapy 2, 51-6.
4. Wise, R. (1986). The clinical relevance of protein binding and tissue concentrations in antimicrobial therapy. Clinical Pharmaco-kinetics 11, 470-82.
5. Eliopoulos, G. M. & Eliopoulos, C. T. (1993). Activity in vitro of the quinolones. In Quinolone Antibacterial Agents, 2nd edn (Hooper, D. C. & Wolfson, J. S., Eds), pp. 161-83. American Society for Microbiology, Washington, DC.
6. Unertl, K. E., Lenhart, F. P., Forst, H., Vogler, G., Wilm, V., Ehret, W. et al. (1989). Ciprofloxacin in the treatment of legionellosis in critically ill patients including those cases unresponsive to erythromycin. American Journal of Medicine 87, 128S-31S.
7. Fitzgeorge, R. B., Gibson, D. H., Jepras, R. & Baskerville, A. (1985). Studies on ciprofloxacin therapy of experimental Legionnaires' disease. Journal of Infection 10, 194-203.
8. Havlichek, D., Pohlod, D. & Saravolatz, L. (1987). Comparison of ciprofloxacin and rifampicin in experimental Legionella pneumophila pneumonia. Journal of Antimicrobial Chemotherapy 20, 875-81.
9. Havlichek, D., Saravolatz, L. & Pohlod, D. (1987). Effect of quinolones and other antimicrobial agents on cell-associated Legionella pneumophila. Antimicrobial Agents and Chemotherapy 31, 1529-34.
10. Hooper, T. L., Gould, F. K., Swinburn, C. R., Featherstone, G., Odom, N. J., Corris, P. A. et al. (1988). Ciprofloxacin: a preferred treatment for Legionella infections in patients receiving cyclosporin A. Journal of Antimicrobial Agents and Chemotherapy 22, 952-3.
11. Ruckdeschel, G., Ehret, W. & Ahl, A. (1984). Susceptibility of Legionella spp. to quinolone derivatives and related organic acids. European Journal of Clinical Microbiology 2, 373.
12. Saito, A., Koga, H., Shigeno, H., Watanabe, K., Mori, K., Kohno, S. et al. (1986). The antimicrobial activity of ciprofloxacin against Legionella species and the treatment of experimental Legionella pneumonia in guinea pigs. Journal of Antimicrobial Chemotherapy 18, 251-60.
13. Edelstein, P. H. (1995). Antimicrobial chemotherapy for legionnaires' disease: a review. Clinical Infectious Diseases 21, S265-76.
14. Liebers, D. M., Baltch, A. L., Hammer, M. C. & Conroy, J. V. (1989). Suceptibility of Legionella pneumophila to eight antimicrobial agents including four macrolides under different assay conditions. Journal of Antimicrobial Chemotherapy 23, 37-41.
15. Edelstein, P. H., Pasiecznik, K. A., Yasui, V. K. & Meyer, R. D. (1982). Susceptibility of Legionella spp. to mycinamicin I and II and other macrolide antibiotics: effect of media composition and origin of organisms. Antimicrobial Agents and Chemotherapy 22, 90-3.
16. Pohlod, D. J., Saravolartz, L. D., Quinn, E. L. & Somerville, M. M. (1981). The effect of inoculum, culture medium and antimicrobial combinations on the in-vitro susceptibilities of Legionella pneumophila. Journal of Antimicrobial Chemotherapy 7, 335-41.
17. Bornstein, N., Roudier, C. & Fleurette, J. (1982). Problèmes pratiques posés par la détermination des concentrations inhibitrices d'antibiotiques chez les Legionella. Pathologie Biologie 30, 421-5.
18. Pendland, S. L., Martin, S. J., Chen, C., Schreckenberger, P. C. & Danziger, L. H. (1997). Comparison of charcoal-and starch-based media for testing susceptibilities Legionella species to macrolides, azalides and fluoroquinolones. Journal of Clinical Microbiology 35, 3004-6.
19. Souli, M., Wennersten, C. B. & Eliopoulos, G. M. (1997). In vitro activity of BAY 12-8039, a novel 8-methoxyquinolone, against species representative of respiratory tract pathogens. In Program and Abstracts of the Thirty-Seventh Interscience Conference on Antimicrobial Agents and Chemotherapy, Toronto, Ontario, Canada 1997. Poster No. F126. American Society for Microbiology, Washington, DC.
20. Hoogkamp-Korstanje, J. A. A. (1997). In-vitro activities of ciprofloxacin, levofloxacin, lomefloxacin, ofloxacin, pefloxacin, sparfloxacin and trovafloxacin against Gram-positive and Gram-negative pathogens from respiratory tract infections. Journal of Antimicrobial Chemotherapy 40, 427-31.
21. Meyer, R. D. (1983). Legionella infections: a review of five years of research. Reviews of Infectious Diseases 5, 258-78.
22. Dalhoff, A. & Bergan, T. (1998). Pharmacokinetics of fluoroquinolones in experimental animals. In Handbook of Experimental Pharmacology, Volume 127 (Kuhlmann, J., Dalhoff, A. & Zeiler, H.-J., Eds), pp. 179-206. Springer-Verlag, Berlin.
23. Pascual, A., Garcia, I., Ballesta, S. & Perea, E. J. (1997). Uptake and intracellular activity of BAY 12-8039 in human neutrophils and tissue-cultured epithelial cells. In Program and Abstracts of the Thirty-Seventh Interscience Conference on Antimicrobial Agents and Chemotherapy, Toronto, Ontario, Canada, 1997. Poster No. F149. American Society for Microbiology, Washington, DC.